Back to top
more

Zimmer Biomet (ZBH)

(Delayed Data from NYSE)

$119.35 USD

119.35
1,099,144

-0.40 (-0.33%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $119.32 -0.03 (-0.03%) 4:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (140 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.

Why Is Zimmer (ZBH) Up 10.8% Since Last Earnings Report?

by Zacks Equity Research

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Zimmer Biomet (ZBH) for Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH), driven by a recovery in business and an expanding global footprint.

Why Zimmer Biomet (ZBH) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zimmer Biomet's (ZBH) Knee Sales Robust, Macro Woes Hurt

by Zacks Equity Research

Zimmer Biomet (ZBH) is working to strengthen its foothold in emerging markets that provide long-term opportunities for growth.

Zimmer Biomet (ZBH) Q3 Earnings Top Estimates, Margins Fall

by Zacks Equity Research

Zimmer Biomet (ZBH) gains from solid strategic execution and increasing traction in innovations in the third quarter.

Zimmer (ZBH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Zimmer (ZBH) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zimmer Biomet (ZBH) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Zimmer (ZBH) delivered earnings and revenue surprises of 3.77% and 0.64%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Why Zimmer Biomet (ZBH) Might Surprise This Earnings Season

by Zacks Equity Research

Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Stay Ahead of the Game With Zimmer (ZBH) Q3 Earnings: Wall Street's Insights on Key Metrics

by Zacks Equity Research

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Zimmer (ZBH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2023.

Zimmer Biomet (ZBH) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Zimmer Biomet (ZBH) Beat Estimates This Earnings Season?

by Zacks Equity Research

Zimmer Biomet (ZBH) is expected to have witnessed strong performance across Avenir Complete hip.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Ecolab (ECL) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Ecolab's (ECL) third-quarter results are likely to reflect continued segmental strength.

ZBH or ABT: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ZBH vs. ABT: Which Stock Is the Better Value Option?

Nalak Das headshot

5 Large-Cap Stocks to Buy on the Dip for Q4 2023

by Nalak Das

We have narrowed our search to five large-cap (market capital > $10 billion) stocks with attractive valuations. These stocks are: TWLO, KDP, ULTA, ALGN, ZBH.

Indrajit Bandyopadhyay headshot

5 Medical Product Stocks to Buy Amid Industry Recovery

by Indrajit Bandyopadhyay

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. SYK, BSX, ZBH, PODD and HAE are well-poised to gain from the favorable factors.

Here's Why You Should Retain Zimmer Biomet (ZBH) for Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH) on business recovery and expansion in emerging markets.

Zimmer Biomet (ZBH) Gains From ROSA Sales Growth Amid FX Woes

by Zacks Equity Research

Zimmer Biomet (ZBH) plans to work on the overall shift of the company's legacy knee systems to a fully rounded-out Persona portfolio.

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zimmer Biomet (ZBH) Business Recovery Continues Despite FX Woe

by Zacks Equity Research

Zimmer Biomet (ZBH) is benefiting from increased provider capacity, resulting in backlog pull-through in the recent quarters.

Here's Why You Should Retain Zimmer Biomet (ZBH) for Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH) due to innovative new product launches and solid execution.

National Vision (EYE) Gains From Store Openings Amid Cost Woes

by Zacks Equity Research

National Vision (EYE) continues to roll out its remote care capabilities, which provide doctors with additional levels of flexibility and expand exam capacity in many areas.

Here's Why You Should Buy SmileDirectClub (SDC) Stock Now

by Zacks Equity Research

Investors are likely to benefit from the SmileDirectClub (SDC) stock, backed by strategic alliances and targeted long-term growth.

Zimmer Biomet (ZBH) Q2 Earnings Match Estimates, View Raised

by Zacks Equity Research

Barring S.E.T., Zimmer Biomet (ZBH) records strong growth across each of its business segments in the second quarter.

Zimmer (ZBH) Reports Q2 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for Zimmer (ZBH) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.